VB-111 in Surgically Accessible Recurrent/Progressive GBM
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04406272 |
|
Recruitment Status :
Active, not recruiting
First Posted : May 28, 2020
Last Update Posted : March 26, 2024
|
Sponsor:
Dana-Farber Cancer Institute
Collaborator:
Vascular Biogenics Ltd. operating as VBL Therapeutics
Information provided by (Responsible Party):
Patrick Wen, MD, Dana-Farber Cancer Institute
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Active, not recruiting |
|---|---|
| Estimated Primary Completion Date : | August 1, 2024 |
| Estimated Study Completion Date : | August 1, 2024 |